Trimedyne sues Bard for breach of Urolase marketing agreement.
This article was originally published in The Gray Sheet
Executive Summary
TRIMEDYNE SEEKING AT LEAST $72 MIL. FROM BARD IN UROLASE LITIGATION, according to a complaint filed Oct. 6 in the Superior Court of the State of California, Orange County division. Trimedyne claims that Bard willfully neglected a 1991 contract between the two companies relating to the marketing and distribution of the Urolase side-firing laser fiber. The suit specifically charges Bard with breach of contract, fraud, negligent misrepresentation, and failure to pay Trimedyne for expenses agreed upon under terms of the contract.